

Johnson & Johnson
Second Quarter 2026
Other Financial Disclosures
Table of Contents

<u>Table 1: Sales by Segment</u>	1
<u>Table 2: Sales by Geographic Area</u>	2
<u>Table 3: Sales of Key Products/Franchises</u>	3 - 7
<u>Table 4: Condensed Consolidated Statement of Earnings - QTD</u>	8
<u>Table 5: Condensed Consolidated Statement of Earnings - YTD</u>	9
<u>Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD</u>	10
<u>Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD</u>	11
<u>Table 8: Non-GAAP Adjusted Net Earnings</u>	12
<u>Table 9: Non-GAAP P&L by Segment Reconciliation 2026 - QTD</u>	13
<u>Table 10: Non-GAAP P&L by Segment Reconciliation 2025 - QTD</u>	14
<u>Table 11: Non-GAAP P&L by Segment Reconciliation 2026 - YTD</u>	15
<u>Table 12: Non-GAAP P&L by Segment Reconciliation 2025 - YTD</u>	16

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)

SECOND QUARTER

				Percent Change	
				Operations	Currency
	2026	2025	Total		
Sales to customers by segment of business					
Innovative Medicine					
U.S.	\$ 9,979	9,161	8.9 %	8.9	-
International	6,405	6,041	6.0	3.6	2.4
	16,384	15,202	7.8	6.8	1.0
MedTech					
U.S.	4,554	4,383	3.9	3.9	-
International	4,372	4,158	5.2	3.2	2.0
	8,926	8,541	4.5	3.6	0.9
U.S.	14,533	13,544	7.3	7.3	-
International	10,777	10,199	5.7	3.4	2.3
Worldwide	\$ 25,310	23,743	6.6 %	5.6	1.0

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

SIX MONTHS

				Percent Change	
				Operations	Currency
	2026	2025	Total		
	\$ 18,850	17,253	9.3 %	9.3	-
	12,960	11,822	9.6	3.9	5.7
	31,810	29,075	9.4	7.1	2.3
	9,013	8,596	4.8	4.8	-
	8,549	7,965	7.3	3.2	4.1
	17,562	16,561	6.0	4.1	1.9
	27,863	25,849	7.8	7.8	-
	21,509	19,787	8.7	3.6	5.1
	\$ 49,372	45,636	8.2 %	6.0	2.2

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)		SECOND QUARTER				
				Percent Change		
	2026	2025	Total	Operational	Currency	
Sales to customers by geographic area						
U.S.	\$ 14,533	13,544	7.3 %	7.3	-	
Europe	5,726	5,387	6.3	3.3	3.0	
Western Hemisphere excluding U.S.	1,309	1,206	8.5	2.7	5.8	
Asia-Pacific, Africa	3,742	3,606	3.8	3.9	(0.1)	
International	10,777	10,199	5.7	3.4	2.3	
Worldwide	\$ 25,310	23,743	6.6 %	5.6	1.0	

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

		SIX MONTHS				
				Percent Change		
	2026	2025	Total	Operational	Currency	
	\$ 27,863	25,849	7.8 %	7.8	-	
	11,574	10,497	10.3	3.0	7.3	
	2,602	2,373	9.6	2.6	7.0	
	7,333	6,917	6.0	4.9	1.1	
	21,509	19,787	8.7	3.6	5.1	
	\$ 49,372	45,636	8.2 %	6.0	2.2	

INNOVATIVE MEDICINE SEGMENT ⁽²⁾

ONCOLOGY

US
Intl
WW
DARZALEX
US
Intl
WW

CARVYKTI

US
Intl
WW

TECVAYLI

US
Intl
WW

TALVEY

US
Intl
WW

RYBREVA NT / LAZCLUZE

US
Intl
WW

ERLEADA

US
Intl
WW

IMBRUVICA

US
Intl
WW

OTHER ONCOLOGY ⁽³⁾

US
Intl
WW

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
SECOND QUARTER					
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
	\$ 4,069	3,385	20.3%	20.3%	-
	3,337	2,928	14.0%	11.2%	2.8%
	7,406	6,312	17.3%	16.1%	1.2%
	2,435	2,017	20.7%	20.7%	-
	1,772	1,521	16.4%	13.5%	2.9%
	4,207	3,539	18.9%	17.6%	1.3%
	472	358	31.7%	31.7%	-
	185	81	*	*	*
	657	439	49.4%	47.7%	1.7%
	186	114	63.9%	63.9%	-
	74	52	40.7%	39.2%	1.5%
	260	166	56.5%	56.1%	0.4%
	112	82	36.2%	36.2%	-
	62	24	*	*	*
	174	106	63.3%	62.6%	0.7%
	190	139	36.8%	36.8%	-
	99	41	*	*	*
	289	179	60.8%	61.6%	(0.8)%
	396	378	4.7%	4.7%	-
	599	530	12.9%	9.7%	3.2%
	995	908	9.5%	7.6%	1.9%
	149	239	(37.6)%	(37.6)%	-
	449	496	(9.5)%	(11.8)%	2.3%
	599	735	(18.6)%	(20.2)%	1.6%
	131	56	*	*	-
	97	181	(46.5)%	(45.7)%	(0.8)%
	226	238	(4.6)%	(3.9)%	(0.7)%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
SIX MONTHS					
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
	\$ 7,684	6,398	20.1%	20.1%	-
	6,695	5,592	19.7%	13.2%	6.5%
	14,379	11,990	19.9%	16.9%	3.0%
	4,643	3,846	20.7%	20.7%	-
	3,528	2,930	20.4%	13.7%	6.7%
	8,171	6,776	20.6%	17.7%	2.9%
	905	676	33.8%	33.8%	-
	349	132	*	*	*
	1,254	808	55.1%	52.1%	3.0%
	313	219	43.1%	43.1%	-
	148	98	51.1%	45.2%	5.9%
	462	317	45.5%	43.7%	1.8%
	213	150	41.7%	41.7%	-
	113	42	*	*	*
	326	192	69.3%	67.2%	2.1%
	365	252	45.0%	45.0%	-
	181	69	*	*	*
	546	320	70.4%	69.9%	0.5%
	738	670	10.2%	10.2%	-
	1,206	1,009	19.4%	12.5%	6.9%
	1,944	1,679	15.8%	11.6%	4.2%
	292	474	(38.4)%	(38.4)%	-
	966	970	(0.4)%	(6.7)%	6.3%
	1,259	1,444	(12.9)%	(17.1)%	4.2%
	216	110	94.5%	94.5%	-
	203	341	(40.5)%	(41.3)%	0.8%
	418	452	(7.4)%	(8.0)%	0.6%

See footnotes at end of schedule

IMMUNOLOGY

US

Intl

WW

TREMFYA

US

Intl

WW

SIMPONI / SIMPONI ARIA

US

Intl

WW

REMICADE

US

US Exports ⁽⁴⁾

Intl

WW

STELARA

US

Intl

WW

OTHER IMMUNOLOGY

US

Intl

WW

NEUROSCIENCE

US

Intl

WW

SPRAVATO

US

Intl

WW

CAPLYTA ⁽⁵⁾

US

Intl

WW

INVEGA SUSTENNA / XEPLION /

INVEGA TRINZA / TREVICTA

US

Intl

WW

CONCERTA / Methylphenidate

US

Intl

WW

OTHER NEUROSCIENCE

US

Intl

WW

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SECOND QUARTER

	<u>2026</u>	<u>2025</u>	<u>% Change</u>		<u>Currency</u>
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	
	\$		(5.3)%	(5.3)%	-
	2,372	2,505	(1.0)%	(3.5)%	2.5%
	1,473	1,489	(3.7)%	(4.6)%	0.9%
	3,844	3,993			
	1,465	796	84.2%	84.2%	-
	581	391	48.7%	44.2%	4.5%
	2,046	1,186	72.5%	71.0%	1.5%
	260	305	(14.6)%	(14.6)%	-
	358	387	(7.3)%	(9.5)%	2.2%
	618	690	(10.5)%	(11.7)%	1.2%
	215	283	(24.1)%	(24.1)%	-
	10	34	(71.0)%	(71.0)%	-
	112	138	(18.4)%	(20.5)%	2.1%
	338	455	(25.8)%	(26.4)%	0.6%
	336	1,078	(68.8)%	(68.8)%	-
	404	575	(29.7)%	(31.1)%	1.4%
	740	1,653	(55.2)%	(55.7)%	0.5%
	85	8	*	*	-
	18	0	*	*	*
	104	8	*	*	*
	1,659	1,377	20.5%	20.5%	-
	678	674	0.6%	(1.1)%	1.7%
	2,337	2,051	14.0%	13.4%	0.6%
	514	366	40.7%	40.7%	-
	70	50	41.2%	34.7%	6.5%
	584	414	40.8%	40.0%	0.8%
	361	211	70.9%	70.9%	-
	-	-	-	-	-
	361	211	70.9%	70.9%	-
	738	732	0.8%	0.8%	-
	278	260	6.6%	5.1%	1.5%
	1,015	992	2.3%	1.9%	0.4%
	12	24	(48.6)%	(48.6)%	-
	133	139	(4.2)%	(4.8)%	0.6%
	146	164	(10.8)%	(11.3)%	0.5%
	34	45	(22.9)%	(22.9)%	-
	198	226	(12.3)%	(13.7)%	1.4%
	232	270	(14.0)%	(15.2)%	1.2%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SIX MONTHS

	<u>2026</u>	<u>2025</u>	<u>% Change</u>		<u>Currency</u>
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	
	\$		(10.1)%	(10.1)%	-
	4,227	4,701	(0.1)%	(5.0)%	4.9%
	2,997	2,999	(6.2)%	(8.1)%	1.9%
	7,224	7,700			
	2,507	1,395	79.7%	79.7%	-
	1,147	747	53.6%	45.5%	8.1%
	3,654	2,142	70.6%	67.8%	2.8%
	529	597	(11.2)%	(11.2)%	-
	736	753	(2.3)%	(6.9)%	4.6%
	1,265	1,349	(6.2)%	(8.8)%	2.6%
	484	597	(19.0)%	(19.0)%	-
	28	44	(37.1)%	(37.1)%	-
	248	281	(11.5)%	(15.4)%	3.9%
	760	922	(17.6)%	(18.7)%	1.1%
	556	2,059	(73.0)%	(73.0)%	-
	839	1,219	(31.1)%	(34.6)%	3.5%
	1,396	3,278	(57.4)%	(58.7)%	1.3%
	123	9	*	*	-
	27	0	*	*	*
	150	9	*	*	*
	3,153	2,345	34.5%	34.5%	-
	1,359	1,353	0.4%	(3.7)%	4.1%
	4,512	3,698	22.0%	20.5%	1.5%
	920	642	43.4%	43.4%	-
	131	93	41.8%	31.9%	9.9%
	1,052	734	43.2%	42.0%	1.2%
	631	211	*	*	-
	-	-	-	-	-
	631	211	*	*	-
	1,496	1,357	10.2%	10.2%	-
	558	537	3.7%	(0.1)%	3.8%
	2,053	1,895	8.4%	7.3%	1.1%
	34	62	(45.5)%	(45.5)%	-
	248	249	(0.4)%	(3.0)%	2.6%
	282	312	(9.5)%	(11.5)%	2.0%
	72	73	(1.1)%	(1.1)%	-
	422	474	(10.9)%	(15.1)%	4.2%
	494	547	(9.6)%	(13.2)%	3.6%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER				
			% Change		
	2026	2025	Reported	Operational ⁽¹⁾	Currency
<u>PULMONARY HYPERTENSION (PH)</u>					
US	\$ 814	799	1.8%	1.8%	-
Intl	329	314	4.9%	3.4%	1.5%
WW	1,143	1,113	2.6%	2.2%	0.4%
<u>UPTRAVI</u>					
US	386	382	1.0%	1.0%	-
Intl	108	94	15.0%	10.1%	4.9%
WW	494	476	3.8%	2.8%	1.0%
<u>OPSUMIT / OPSYNVI</u>					
US	416	403	3.2%	3.2%	-
Intl	187	180	3.9%	3.6%	0.3%
WW	602	582	3.4%	3.3%	0.1%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	13	16	(16.9)%	(16.9)%	-
Intl	34	40	(14.3)%	(12.7)%	(1.6)%
WW	47	55	(15.0)%	(13.9)%	(1.1)%
<u>INFECTIOUS DISEASES (ID)</u>					
US	300	320	(6.3)%	(6.3)%	-
Intl	463	484	(4.1)%	(6.2)%	2.1%
WW	763	803	(5.0)%	(6.3)%	1.3%
<u>EDURANT / rilpivirine</u>					
US	3	6	(49.6)%	(49.6)%	-
Intl	347	354	(1.9)%	(3.8)%	1.9%
WW	350	360	(2.7)%	(4.6)%	1.9%
<u>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</u>					
US	296	312	(5.1)%	(5.1)%	-
Intl	76	85	(10.4)%	(12.8)%	2.4%
WW	372	396	(6.3)%	(6.8)%	0.5%
<u>OTHER INFECTIOUS DISEASES</u>					
US	1	2	(47.9)%	(47.9)%	-
Intl	40	45	(9.6)%	(12.8)%	3.2%
WW	41	47	(11.6)%	(14.6)%	3.0%
<u>CARDIOVASCULAR / METABOLISM / OTHER (CVM)</u>					
US	765	776	(1.3)%	(1.3)%	-
Intl	124	154	(19.4)%	(21.5)%	2.1%
WW	889	930	(4.3)%	(4.7)%	0.4%
<u>XARELTO</u>					
US	664	621	7.1%	7.1%	-
Intl	-	-	-	-	-
WW	664	621	7.1%	7.1%	-
<u>OTHER</u>					
US	101	155	(35.0)%	(35.0)%	-
Intl	124	154	(19.4)%	(21.5)%	2.1%
WW	225	309	(27.2)%	(28.3)%	1.1%
<u>TOTAL PH, ID, CVM</u>					
US	1,878	1,895	(0.9)%	(0.9)%	-
Intl	916	952	(3.6)%	(5.5)%	1.9%
WW	2,795	2,846	(1.8)%	(2.4)%	0.6%
<u>TOTAL INNOVATIVE MEDICINE</u>					
US	9,979	9,161	8.9%	8.9%	-
Intl	6,405	6,041	6.0%	3.6%	2.4%
WW	\$ 16,384	15,202	7.8%	6.8%	1.0%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SIX MONTHS				
			% Change		
	2026	2025	Reported	Operational ⁽¹⁾	Currency
	\$ 1,645	1,543	6.5%	6.5%	-
	633	595	6.4%	2.3%	4.1%
	2,278	2,138	6.5%	5.4%	1.1%
	771	747	3.2%	3.2%	-
	206	180	14.7%	7.7%	7.0%
	977	927	5.4%	4.0%	1.4%
	849	766	10.9%	10.9%	-
	359	339	6.1%	2.7%	3.4%
	1,208	1,104	9.4%	8.4%	1.0%
	25	31	(19.0)%	(19.0)%	-
	68	77	(11.5)%	(12.3)%	0.8%
	93	107	(13.6)%	(14.2)%	0.6%
	642	635	1.1%	1.1%	-
	1,010	971	4.1%	(2.5)%	6.6%
	1,652	1,605	2.9%	(1.1)%	4.0%
	10	14	(29.3)%	(29.3)%	-
	749	704	6.4%	(0.3)%	6.7%
	759	718	5.7%	(0.9)%	6.6%
	630	617	2.1%	2.1%	-
	185	183	1.2%	(5.6)%	6.8%
	815	799	1.9%	0.4%	1.5%
	2	4	(51.6)%	(51.6)%	-
	76	84	(9.0)%	(13.7)%	4.7%
	78	88	(11.1)%	(15.5)%	4.4%
	1,499	1,631	(8.1)%	(8.1)%	-
	266	312	(14.8)%	(19.5)%	4.7%
	1,765	1,943	(9.2)%	(9.9)%	0.7%
	1,306	1,311	(0.3)%	(0.3)%	-
	-	-	-	-	-
	1,306	1,311	(0.3)%	(0.3)%	-
	192	320	(39.9)%	(39.9)%	-
	266	312	(14.8)%	(19.5)%	4.7%
	458	632	(27.5)%	(29.8)%	2.3%
	3,785	3,809	(0.6)%	(0.6)%	-
	1,909	1,878	1.7%	(3.8)%	5.5%
	5,694	5,686	0.1%	(1.7)%	1.8%
	18,850	17,253	9.3%	9.3%	-
	12,960	11,822	9.6%	3.9%	5.7%
	\$ 31,810	29,075	9.4%	7.1%	2.3%

MEDTECH SEGMENT ⁽²⁾

CARDIOVASCULAR

US

Intl

WW

ELECTROPHYSIOLOGY

US

Intl

WW

ABIOMED

US

Intl

WW

SHOCKWAVE

US

Intl

WW

OTHER CARDIOVASCULAR

US

Intl

WW

SURGERY

US

Intl

WW

ADVANCED

US

Intl

WW

GENERAL

US

Intl

WW

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SECOND QUARTER					
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
	\$				
	1,426	1,364	4.5%	4.5%	-
	978	948	3.2%	1.1%	2.1%
	2,404	2,313	4.0%	3.1%	0.9%
	783	741	5.8%	5.8%	-
	749	728	2.9%	0.4%	2.5%
	1,533	1,468	4.4%	3.1%	1.3%
	342	360	(4.8)%	(4.8)%	-
	97	89	9.5%	9.2%	0.3%
	440	448	(2.0)%	(2.0)%	0.0%
	268	233	14.6%	14.6%	-
	67	58	14.5%	15.4%	(0.9)%
	335	292	14.6%	14.7%	(0.1)%
	33	31	5.5%	5.5%	-
	65	72	(10.5)%	(13.2)%	2.7%
	98	104	(5.7)%	(7.5)%	1.8%
	1,094	1,043	5.0%	5.0%	-
	1,559	1,512	3.1%	0.5%	2.6%
	2,653	2,555	3.9%	2.3%	1.6%
	499	477	4.7%	4.7%	-
	691	687	0.5%	(1.9)%	2.4%
	1,189	1,164	2.2%	0.8%	1.4%
	596	567	5.2%	5.2%	-
	868	825	5.3%	2.5%	2.8%
	1,464	1,391	5.2%	3.6%	1.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SIX MONTHS					
	2026	2025	% Change		
			Reported	Operational ⁽¹⁾	Currency
	\$				
	2,825	2,625	7.6%	7.6%	-
	1,956	1,790	9.3%	5.2%	4.1%
	4,781	4,416	8.3%	6.6%	1.7%
	1,519	1,425	6.6%	6.6%	-
	1,502	1,366	10.0%	5.6%	4.4%
	3,022	2,791	8.3%	6.2%	2.1%
	731	699	4.6%	4.6%	-
	197	170	16.1%	11.4%	4.7%
	928	868	6.8%	5.9%	0.9%
	510	439	16.1%	16.1%	-
	130	110	17.7%	17.2%	0.5%
	640	550	16.4%	16.3%	0.1%
	65	63	3.1%	3.1%	-
	127	144	(11.9)%	(15.3)%	3.4%
	192	207	(7.4)%	(9.7)%	2.3%
	2,140	2,045	4.7%	4.7%	-
	3,024	2,906	4.1%	(0.3)%	4.4%
	5,164	4,951	4.3%	1.8%	2.5%
	976	934	4.5%	4.5%	-
	1,337	1,303	2.6%	(1.4)%	4.0%
	2,312	2,237	3.4%	1.0%	2.4%
	1,165	1,111	4.8%	4.8%	-
	1,687	1,603	5.2%	0.7%	4.5%
	2,852	2,714	5.1%	2.4%	2.7%

See footnotes at end of schedule

VISION

US

Intl

WW

CONTACT LENSES / OTHER

US

Intl

WW

SURGICAL

US

Intl

WW

ORTHOPAEDICS

US

Intl

WW

HIPS

US

Intl

WW

KNEES

US

Intl

WW

TRAUMA

US

Intl

WW

SPINE, SPORTS & OTHER

US

Intl

WW

TOTAL MEDTECH

US

Intl

WW

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
SECOND QUARTER					
	<u>2026</u>	<u>2025</u>	% Change		
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	<u>Currency</u>
	\$ 565	557	1.4%	1.4%	-
	887	813	9.1%	8.5%	0.6%
	1,451	1,369	6.0%	5.6%	0.4%
	445	429	3.6%	3.6%	-
	580	536	8.1%	7.9%	0.2%
	1,025	965	6.1%	6.0%	0.1%
	120	128	(6.0)%	(6.0)%	-
	306	277	10.9%	9.6%	1.3%
	426	403	5.6%	4.7%	0.9%
	1,470	1,420	3.5%	3.5%	-
	948	885	7.2%	5.3%	1.9%
	2,418	2,305	4.9%	4.2%	0.7%
	283	271	4.6%	4.6%	-
	158	150	5.5%	3.0%	2.5%
	441	421	4.9%	4.0%	0.9%
	228	226	1.1%	1.1%	-
	182	164	11.4%	10.3%	1.1%
	410	389	5.5%	5.0%	0.5%
	536	501	6.7%	6.7%	-
	291	267	9.2%	7.4%	1.8%
	827	768	7.6%	6.9%	0.7%
	423	422	0.2%	0.2%	-
	317	305	4.0%	1.9%	2.1%
	740	727	1.8%	0.9%	0.9%
	4,554	4,383	3.9%	3.9%	-
	4,372	4,158	5.2%	3.2%	2.0%
	\$ 8,926	8,541	4.5%	3.6%	0.9%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
SIX MONTHS					
	<u>2026</u>	<u>2025</u>	% Change		
			<u>Reported</u>	<u>Operational ⁽¹⁾</u>	<u>Currency</u>
	\$ 1,144	1,123	1.9%	1.9%	-
	1,672	1,526	9.6%	6.7%	2.9%
	2,816	2,648	6.3%	4.6%	1.7%
	913	881	3.7%	3.7%	-
	1,081	1,003	7.7%	5.0%	2.7%
	1,994	1,884	5.8%	4.4%	1.4%
	231	242	(4.5)%	(4.5)%	-
	591	523	13.1%	9.8%	3.3%
	822	764	7.5%	5.3%	2.2%
	2,905	2,804	3.6%	3.6%	-
	1,896	1,742	8.9%	3.9%	5.0%
	4,801	4,546	5.6%	3.7%	1.9%
	560	534	4.9%	4.9%	-
	317	296	7.2%	1.7%	5.5%
	877	830	5.7%	3.8%	1.9%
	467	457	2.2%	2.2%	-
	363	322	13.0%	8.4%	4.6%
	830	778	6.7%	4.8%	1.9%
	1,068	1,003	6.4%	6.4%	-
	592	537	10.3%	5.2%	5.1%
	1,660	1,540	7.8%	6.0%	1.8%
	810	810	0.0%	0.0%	-
	624	588	6.1%	1.3%	4.8%
	1,434	1,398	2.6%	0.6%	2.0%
	9,013	8,596	4.8%	4.8%	-
	8,549	7,965	7.3%	3.2%	4.1%
	\$ 17,562	16,561	6.0%	4.1%	1.9%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Includes the sales of ZYTIGA which were previously disclosed separately

(4) Reported as U.S. sales

(5) Acquired with Intra-Cellular Therapies on April 2, 2025

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

	2026		2025		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 25,310	100.0	\$ 23,743	100.0	6.6
Cost of products sold	8,051	31.8	7,628	32.1	5.5
Gross Profit	17,259	68.2	16,115	67.9	7.1
Selling, marketing and administrative expenses	6,432	25.4	5,889	24.8	9.2
Research and development expense	3,653	14.4	3,516	14.8	3.9
Interest (income) expense, net	62	0.2	48	0.2	
Other (income) expense, net	331	1.3	107	0.5	
Restructuring	34	0.2	64	0.3	
Earnings before provision for taxes on income	6,747	26.7	6,491	27.3	3.9
Provision for taxes on income	1,213	4.8	954	4.0	27.1
Net earnings	\$ 5,534	21.9	\$ 5,537	23.3	(0.1)
Net earnings per share (Diluted)	\$ 2.27		\$ 2.29		(0.9)
Average shares outstanding (Diluted)	2,440.1		2,419.1		
Effective tax rate	18.0 %		14.7 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 8,660	34.2	\$ 8,188	34.5	5.8
Net earnings	\$ 7,081	28.0	\$ 6,699	28.2	5.7
Net earnings per share (Diluted)	\$ 2.90		\$ 2.77		4.7
Effective tax rate	18.2 %		18.2 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

	2026		2025		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 49,372	100.0	\$ 45,636	100.0	8.2
Cost of products sold	16,157	32.7	14,985	32.8	7.8
Gross Profit	33,215	67.3	30,651	67.2	8.4
Selling, marketing and administrative expenses	12,466	25.3	11,001	24.1	13.3
Research and development expense	7,180	14.5	6,741	14.8	6.5
In-process research and development impairments	36	0.1	-	-	
Interest (income) expense, net	105	0.2	(80)	(0.2)	
Other (income) expense, net	625	1.3	(7,214)	(15.8)	
Restructuring	66	0.1	81	0.2	
Earnings before provision for taxes on income	12,737	25.8	20,122	44.1	(36.7)
Provision for taxes on income	1,968	4.0	3,586	7.9	(45.1)
Net earnings	\$ 10,769	21.8	\$ 16,536	36.2	(34.9)
Net earnings per share (Diluted)	\$ 4.41		\$ 6.82		(35.3)
Average shares outstanding (Diluted)	2,443.9		2,423.3		
Effective tax rate	15.5 %		17.8 %		

Adjusted earnings before provision for taxes and net earnings (1)

Earnings before provision for taxes on income	\$ 16,481	33.4	\$ 16,199	35.5	1.7
Net earnings	\$ 13,695	27.7	\$ 13,405	29.4	2.2
Net earnings per share (Diluted)	\$ 5.60		\$ 5.53		1.3
Effective tax rate	16.9 %		17.2 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
SECOND QUARTER 2026 ACTUAL vs. 2025 ACTUAL

Segments			
	Innovative Medicine	MedTech	Total
WW As Reported	7.8%	4.5%	6.6%
U.S.	8.9%	3.9%	7.3%
International	6.0%	5.2%	5.7%
WW Currency	1.0	0.9	1.0
U.S.	-	-	-
International	2.4	2.0	2.3
WW Operational	6.8%	3.6%	5.6%
U.S.	8.9%	3.9%	7.3%
International	3.6%	3.2%	3.4%
All Other Acquisitions and Divestitures (A&D)	0.1	0.1	0.1
U.S.	0.0	0.2	0.1
International	0.2	0.0	0.1
WW Adjusted Operational Ex A&D	6.9%	3.7%	5.7%
U.S.	8.9%	4.1%	7.4%
International	3.8%	3.2%	3.5%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
SIX MONTHS 2026 ACTUAL vs. 2025 ACTUAL

Segments			
	Innovative Medicine	MedTech	Total
WW As Reported	9.4%	6.0%	8.2%
U.S.	9.3%	4.8%	7.8%
International	9.6%	7.3%	8.7%
WW Currency	2.3	1.9	2.2
U.S.	-	-	-
International	5.7	4.1	5.1
WW Operational	7.1%	4.1%	6.0%
U.S.	9.3%	4.8%	7.8%
International	3.9%	3.2%	3.6%
Caplyta	(0.9)		(0.6)
U.S.	(1.6)		(1.0)
International	0.0		0.0
All Other Acquisitions and Divestitures (A&D)	0.0	0.1	0.1
U.S.	0.0	0.2	0.1
International	0.2	0.0	0.1
WW Adjusted Operational Ex A&D	6.2%	4.2%	5.5%
U.S.	7.7%	5.0%	6.9%
International	4.1%	3.2%	3.7%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Second Quarter		Six Months Ended	
(Dollars in Millions Except Per Share Data)	2026	2025	2026	2025
Net Earnings, after tax- as reported	\$5,534	\$5,537	\$10,769	\$16,536
<i>Pre-tax Adjustments</i>				
Litigation related	267	57	597	(6,909)
Intangible Asset Amortization expense	1,245	1,267	2,492	2,387
Restructuring related ¹	276	79	338	134
Orthopaedics separation related	258	-	377	-
Acquisition, integration and divestiture related	80	246	176	378
(Gains)/losses on securities	(213)	21	(272)	60
IPR&D impairments	-	-	36	-
Other	-	27	-	27
<i>Tax Adjustments</i>				
Tax impact on special item adjustments ²	(368)	(321)	(792)	994
Tax legislation and other tax related	2	(214)	(26)	(202)
Adjusted Net Earnings , after tax	\$7,081	\$6,699	\$13,695	\$13,405
Average shares outstanding (Diluted)	2,440.1	2,419.1	2,443.9	2,423.3
Adjusted net earnings per share (Diluted)	\$2.90	\$2.77	\$5.60	\$5.53
Operational adjusted net earnings per share (Diluted)	\$2.86		\$5.43	

Notes:

¹ In the fiscal second quarter of 2026, the Company commenced a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between \$650 - \$750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of \$200 million, primarily related to asset impairments, were recorded in the fiscal second quarter of 2026.

In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of \$59 million were recorded in the fiscal second quarter of 2026 (\$114 million Q2 2026 YTD) and \$29 million in the fiscal second quarter of 2025 (\$29 million Q2 2025 YTD) and primarily include costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of \$17 million in the fiscal second quarter of 2026 (\$24 million Q2 2026 YTD) and \$50 million in the fiscal second quarter of 2025 (\$105 million Q2 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately \$1 billion.

² The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Quarter to Date

	Second Quarter June 28, 2026 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Second Quarter June 28, 2026 Non-GAAP
Innovative Medicine									
Cost of products sold	\$ 4,296	(764)		(18)	(9)				3,505
Selling, marketing and admin expenses	3,130								3,130
Research and development expense	2,875								2,875
Other segment items	(166)		91	(182)	(54)	227			(84)
Adjusted Income Before Tax by Segment	6,249	764	(91)	200	63	(227)	-	-	6,958

	Second Quarter June 28, 2026 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Second Quarter June 28, 2026 Non-GAAP
MedTech									
Cost of products sold	\$ 3,737	(481)		(17)			(3)		3,236
Selling, marketing and admin expenses	3,069						(17)		3,052
Research and development expense	778						(2)		776
Other segment items	165		76	(59)	(37)	(14)	(236)		(105)
Adjusted Income Before Tax by Segment	1,177	481	(76)	76	37	14	258	-	1,967

	Second Quarter June 28, 2026 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Second Quarter June 28, 2026 Non-GAAP
Expenses not allocated to segments									
Cost of products sold	\$ 18								18
Selling, marketing and admin expenses	233								233
Research and development expense	-								-
Other segment items	428		(434)		20				14
Adjusted Income Before Tax by Segment	(679)	-	434	-	(20)	-	-	-	(265)

	Second Quarter June 28, 2026 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Second Quarter June 28, 2026 Non-GAAP
Johnson & Johnson Consolidated									
Cost of products sold	\$ 8,051	(1,245)		(35)	(9)		(3)		6,759
Selling, marketing and admin expenses	6,432						(17)		6,415
Research and development expense	3,653						(2)		3,651
Other (Income) / Expense	331		(267)	(207)	(71)	213	(236)		(237)
In-process research and development impairments	-								-
Interest (Income)/Expense	62								62
Restructuring	34			(34)					-
Adjusted Income Before Tax	6,747	1,245	267	276	80	(213)	258	-	8,660
Provision for taxes on income	1,213	239	59	54	23	(50)	43	(2)	1,579
Net Earnings	\$ 5,534	1,006	208	222	57	(163)	215	2	7,081

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Quarter to Date

Innovative Medicine

	Second Quarter June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Second Quarter June 29, 2025 Non-GAAP
Cost of products sold	\$ 3,978	(785)			(13)				3,180
Selling, marketing and admin expenses	2,789								2,789
Research and development expense	2,869								2,869
Other segment items	14		69		(207)	8		(13)	(129)
Adjusted Income Before Tax by Segment	5,552	785	(69)	-	220	(8)	-	13	6,493

MedTech

	Second Quarter June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Second Quarter June 29, 2025 Non-GAAP
Cost of products sold	\$ 3,638	(482)		(15)	1				3,142
Selling, marketing and admin expenses	2,862								2,862
Research and development expense	647				43				690
Other segment items	190		(83)	(64)	(53)	(29)		(14)	(53)
Adjusted Income Before Tax by Segment	1,204	482	83	79	9	29	-	14	1,900

Expenses not allocated to segments

	Second Quarter June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Second Quarter June 29, 2025 Non-GAAP
Cost of products sold	\$ 12								12
Selling, marketing and admin expenses	238								238
Research and development expense	-								-
Other segment items	15		(43)		(17)				(45)
Adjusted Income Before Tax by Segment	(265)	-	43	-	17	-	-	-	(205)

Johnson & Johnson Consolidated

	Second Quarter June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Second Quarter June 29, 2025 Non-GAAP
Cost of products sold	\$ 7,628	(1,267)		(15)	(12)				6,334
Selling, marketing and admin expenses	5,889								5,889
Research and development expense	3,516				43				3,559
Other (Income) / Expense	107		(57)		(277)	(21)		(27)	(275)
In-process research and development impairments	-								-
Interest (Income)/Expense	48								48
Restructuring	64			(64)					-
Adjusted Income Before Tax	6,491	1,267	57	79	246	21	-	27	8,188
Provision for taxes on income	954	222	9	13	72	5	214	-	1,489
Net Earnings	\$ 5,537	1,045	48	66	174	16	(214)	27	6,699

Year to Date

Innovative Medicine

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation \$ in Millions									
Six Months June 28, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Six Months June 28, 2026 Non-GAAP
\$ 8,686	(1,527)			(18)	(19)				7,122
6,048									6,048
5,688									5,688
(178)		51		(182)	(100)	282			(127)
11,566	1,527	(51)	-	200	119	(282)	-	-	13,079

MedTech

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Six Months June 28, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Six Months June 28, 2026 Non-GAAP
\$ 7,438	(965)			(42)			(3)		6,428
5,975							(17)		5,958
1,492							(2)		1,490
241		117	(36)	(96)	(64)	(10)	(355)		(203)
2,416	965	(117)	36	138	64	10	377	-	3,889

Expenses not allocated to segments

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other segment items
Adjusted Income Before Tax by Segment

Six Months June 28, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Six Months June 28, 2026 Non-GAAP
\$ 33									33
443									443
-									-
769		(765)			7				11
(1,245)	-	765	-	-	(7)	-	-	-	(487)

Johnson & Johnson Consolidated

Cost of products sold
Selling, marketing and admin expenses
Research and development expense
Other (Income) / Expense
In-process research and development impairments
Interest (Income)/Expense
Restructuring
Adjusted Income Before Tax
Provision for taxes on income
Net Earnings

Six Months June 28, 2026 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Orthopaedics Separation Related	Tax legislation and other tax related	Six Months June 28, 2026 Non-GAAP
\$ 16,157	(2,492)			(60)	(19)		(3)		13,583
12,466							(17)		12,449
7,180							(2)		7,178
625		(597)		(212)	(157)	272	(355)		(424)
36			(36)						-
105									105
66				(66)					-
12,737	2,492	597	36	338	176	(272)	377	-	16,481
1,968	479	131	8	124	45	(63)	68	26	2,786
\$ 10,769	2,013	466	28	214	131	(209)	309	(26)	13,695

Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
\$ in Millions

Year to Date

	Six Months June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Six Months June 29, 2025 Non-GAAP
<i>Innovative Medicine</i>									
Cost of products sold	\$ 7,998	(1,434)			(13)				6,551
Selling, marketing and admin expenses	5,050								5,050
Research and development expense	5,417								5,417
Other segment items	(152)	-	69		(227)	(10)		(13)	(333)
Adjusted Income Before Tax by Segment	10,762	1,434	(69)	-	240	10	-	13	12,390

	Six Months June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Six Months June 29, 2025 Non-GAAP
<i>MedTech</i>									
Cost of products sold	\$ 6,964	(953)		(23)	(51)				5,937
Selling, marketing and admin expenses	5,518								5,518
Research and development expense	1,324				37				1,361
Other segment items	130		(83)	(111)	(107)	(50)		(14)	(235)
Adjusted Income Before Tax by Segment	2,625	953	83	134	121	50	-	14	3,980

	Six Months June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Six Months June 29, 2025 Non-GAAP
<i>Expenses not allocated to segments</i>									
Cost of products sold	\$ 23								23
Selling, marketing and admin expenses	433								433
Research and development expense	-								-
Other segment items	(7,191)		6,923		(17)				(285)
Adjusted Income Before Tax by Segment	6,735	-	(6,923)	-	17	-	-	-	(171)

	Six Months June 29, 2025 GAAP	Intangible asset amortization	Litigation related	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Tax legislation and other tax related	Other	Six Months June 29, 2025 Non-GAAP
<i>Johnson & Johnson Consolidated</i>									
Cost of products sold	\$ 14,985	(2,387)		(23)	(64)				12,511
Selling, marketing and admin expenses	11,001								11,001
Research and development expense	6,741				37				6,778
Other (Income) / Expense	(7,214)		6,909	(30)	(351)	(60)		(27)	(773)
In-process research and development impairments	-								-
Interest (Income)/Expense	(80)								(80)
Restructuring	81			(81)					-
Adjusted Income Before Tax	20,122	2,387	(6,909)	134	378	60	-	27	16,199
Provision for taxes on income	3,586	410	(1,544)	24	102	14	202		2,794
Net Earnings	\$ 16,536	1,977	(5,365)	110	276	46	(202)	27	13,405